Lexeo Therapeutics, Inc. (LXEO): Total Assets
$268.69M
As of 2025-12-31
$254.90M
As of 2026-06-30
+40.4%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $268.69M | +82.9% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $146.94M | +5.1% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $139.81M | +44.0% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $97.08M | n/a | 2024-03-11, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $268.69M | +82.9% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $261.04M | +70.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $258.34M | -42.4% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| Alector, Inc. (ALEC) | 2025-12-31 | $293.24M | -37.4% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $293.83M | -3.6% |
Compare LXEO, TECX, IVVD, CHRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗